XX Porto Cancer Meeting
"Drug Resistance in Cancer: from biology to molecular targets and drugs"
Date: 28 and 29 April 2011 Local: IPATIMUP, Porto , Portugal (www.ipatimup.pt) Host Institutions: IPATIMUP and CEQUIMED-UP Scientific Committee: M. Helena Vasconcelos – FFUP and IPATIMUP, Portugal Charles Swanton – CRUK and Royal Marsden Hospital, UK Organizing Committee: M. Helena Vasconcelos (Main Organizer) Gabriela M Almeida Raquel T Lima Hugo Seca Andreia Palmeira Meeting Secretariat: Natália Lima (nlima@ipatimup.pt) MEETING PROGRAM DAY ONE: From the clinic to molecular targets (Sessions I and II) 8:00 Registration 8:45 Welcome: Manuel Sobrinho Simões (IPATIMUP and FMUP), Madalena Pinto (CEQUIMED-UP and FFUP), Charles Swanton (CRUK and Royal Marsden Hospital), M. Helena Vasconcelos (FFUP and IPATIMUP) I – Mechanisms of drug resistance and identification of novel targets Chairs: José E. Guimarães and Manuel Sobrinho-Simões 9:00-9:40 Hermann Lage – Charité, Institute of Pathology, Berlin, Germany “An overview of cancer multidrug resistance: a still unsolved problem” 9:40-10:20 Jean-Pierre Marie - University Pierre & Marie Curie and Saint Antoine Hospital, Paris, France “Pgp as a resistance factor in AML” 10:20-10:50 Coffee break 10:50-11:30 Charles Swanton, CR-UK Translational Cancer Therapeutics Laboratory, “Integrative genomics strategies to identify novel drug resistance mechanisms in cancer” 11:30-12:10 Fernando Schmitt – IPATIMUP and FMUP, Porto, Portugal 12:10-14:10 Lunch break and poster session I (Translational Research posters) II –Translating drug resistance research into patient stratification and personalised medicine Chairs: Luís Costa and Charles Swanton 14:10-14:50 Junia V. Melo - University of Adelaide, Department of Haematology, Centre for Cancer Biology - Adelaide, Australia “Diagnosing, predicting and overcoming resistance to imatinib in chronic myeloid leukaemia” 14:50-15:30 Andrea L. Richardson – Harvard Medical School and Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, MA, USA “Molecular alterations in breast cancer pathobiology: guides for treatment choices” 15:30-16:10 Christos Sotiriou – Institut Jules Bordet, Brussels, Belgium “Genomics and molecular biology in breast cancer: implications for treatment choices and drug development” 16:10-16:40 Coffee break 16:40-17:20 Fabrice André, Institut Gustav Roussy, Villejuif, France “Molecular targets in breast cancer to reverse drug resistance” 17:20-18:00 Dean Fennell- Cancer Research Centre, University of Belfast, Belfast, UK “Targeting cell death pathways in thoracic malignancy” 20:00 Meeting Dinner DAY TWO: Drug resistance, genome instability and tumour stem cells: therapeutic insights (Sessions III and IV) III– Drug resistance: impact of tumour somatic mutations and genome instability Chairs: Raquel Seruca and Christos Sotiriou 9:00-9:40 Jorge S. Reis-Filho - The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK 9:40-10:20 Alberto Inga - Centre for Integrative Biology, CIBIO, University of Trento, Trento, Italy “Impact of distinct p53 mutations on cancer clinical variables” 10:20-10:50 Coffee break 10:50-11:30 Zoltan Szallasi, Children's Hospital, Boston, USA and Technical University of Denmark, Lyngby, Denmark “Genome instability subtype and drug resistance: perspectives from the genomics analysis of breast cancer” 11:30-12:10 Andy Futreal, Wellcome Trust Sanger Institute, Hinxton, UK “Leveraging massively parallel sequencing in somatic cancer genetics” 12:10-14:10 Lunch break and poster session II (Basic Research posters) IV –Targeting drug resistant disease Chairs: M. Helena Vasconcelos and Dean Fennell 14:10-14:50 Cédric Blanpain, Interdisciplinary Research Institute (IRIBHM), Université Libre de Bruxelles (ULB), Brussels, Belgium “The role of cancer stem cells during cancer growth and relapse after therapy” 14:50-15:30 Klaus-Michael Debatin - University of Ulm, Ulm, Germany “Cell death resistance in cancer” 15:30-16:10 Seamus J. Martin – Trinity College, Dublin, Ireland “BH3-only proteins and cell death control” 16:10-16:40 Coffee break 16:40-17:20 Giovanni Gaudino – University of Hawai'i, Cancer Research Center of Hawai'i, Honolulu, USA “Targeting survival and drug resistance in malignant mesothelioma” 17:20-18:00 Madalena M. M. Pinto, FFUP and CEQUIMED-UP, Portugal “Multifunctional novel small-molecules to overcome drug resistance in cancer” 18:00 Adjourn: Charles Swanton (CRUK and Royal Marsden Hospital), M. Helena Vasconcelos (FFUP and IPATIMUP), Madalena Pinto (CEQUIMED-UP and FFUP) and Manuel Sobrinho Simões (IPATIMUP and FMUP)
London Research Institute and Royal Marsden Hospital, London, UK